Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC – OncLive
|
Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC
OncLive … modalities to best determine which therapeutic strategy makes the most sense to inflame an otherwise cold tumor microenvironment will be key. This is one of the biggest areas of research in cancer immunotherapy, in particular for NSCLC, concludes … |
